at Zacks.com (Fri, 5:55PM)
Pharmacyclics (PCYC) tacks on a 6.6%% gain after landing a recommendation from industry-watcher...
Pharmacyclics (PCYC) tacks on a 6.6%% gain after landing a recommendation from industry-watcher John McCamant - who calls the firm one of the most exciting names in biotech. He highlights the company's B-cell lymphoma drug that is in phase 2 and landed a deal with a unit of Johnson & Johnson that includes a $150M upfront payment and a 50/50 profit/loss split worldwide.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 23, 2015)
at Zacks.com (Jan 20, 2015)
at Zacks.com (Jan 16, 2015)
at Benzinga.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs